share_log

基石藥業-B：(1) 建議根據首次公開發售後僱員持股計劃向一名董事兼首席執行官授出購股權；(2) 臨時股東大會通告；及 (3) 就臨時股東大會暫停辦理股份過戶登記手續

CSTONE PHARMA-B: (1) PROPOSED GRANT OF OPTIONS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP; (2) NOTICE OF EXTRAORDINARY GENERAL MEETING; AND (3) CLOSURE OF REGISTER OF MEMBERS FOR THE EXTRAORDINARY GENERAL MEETING

香港交易所 ·  Dec 28, 2023 04:00
Summary by Moomoo AI
基石藥業-B（股份代號：2616）將於2024年1月17日舉行臨時股東大會，以審議向執行董事兼首席執行官楊建新博士授出1,400萬份購股權的提案。該購股權授出是根據公司首次公開發售後僱員持股計劃的條款，並與楊博士達成的業績目標里程碑相關。授出購股權的行使價為每股2.350港元，該價格是授出日期股份收市價與前五個營業日平均收市價中的較高者。此外，公司將於2024年1月12日至17日暫停股份過戶登記，以準備股東大會。股東若欲於大會上投票，須於2024年1月15日上午十時前提交代表委任表格。公司董事會及獨立非執行董事均推薦股東贊成該普通決議案。
基石藥業-B（股份代號：2616）將於2024年1月17日舉行臨時股東大會，以審議向執行董事兼首席執行官楊建新博士授出1,400萬份購股權的提案。該購股權授出是根據公司首次公開發售後僱員持股計劃的條款，並與楊博士達成的業績目標里程碑相關。授出購股權的行使價為每股2.350港元，該價格是授出日期股份收市價與前五個營業日平均收市價中的較高者。此外，公司將於2024年1月12日至17日暫停股份過戶登記，以準備股東大會。股東若欲於大會上投票，須於2024年1月15日上午十時前提交代表委任表格。公司董事會及獨立非執行董事均推薦股東贊成該普通決議案。
KEYSTONE PHARMACEUTICAL-B (STOCK CODE: 2616) WILL HOLD AN INTERIM GENERAL MEETING ON JANUARY 17, 2024 TO CONSIDER THE PROPOSAL TO GRANT A SHARE OPTION TO THE EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER, DR. YANG JIANXIN. THE SHARE OPTION GRANT IS UNDER THE TERMS OF THE COMPANY'S INITIAL PUBLIC OFFERING EMPLOYEE EQUITY PLAN AND IS RELATED TO THE PERFORMANCE TARGET MILESTONES ACHIEVED BY DR. YANG. The exercise price of the share option is HK$2,350 per share, which is higher than the closing price of the shares on the date of issue and the average closing price of the previous five business days. In addition, the Company will suspend the registration of shares from 12 to 17 January 2024 in preparation for the General Meeting. Shareholders who wish to vote at the General Meeting must submit the Proxy Form by 10 a.m. on 15 January 2024. The Board of Directors of the Company and the independent non-executive directors recommend that shareholders approve the ordinary resolution.
KEYSTONE PHARMACEUTICAL-B (STOCK CODE: 2616) WILL HOLD AN INTERIM GENERAL MEETING ON JANUARY 17, 2024 TO CONSIDER THE PROPOSAL TO GRANT A SHARE OPTION TO THE EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER, DR. YANG JIANXIN. THE SHARE OPTION GRANT IS UNDER THE TERMS OF THE COMPANY'S INITIAL PUBLIC OFFERING EMPLOYEE EQUITY PLAN AND IS RELATED TO THE PERFORMANCE TARGET MILESTONES ACHIEVED BY DR. YANG. The exercise price of the share option is HK$2,350 per share, which is higher than the closing price of the shares on the date of issue and the average closing price of the previous five business days. In addition, the Company will suspend the registration of shares from 12 to 17 January 2024 in preparation for the General Meeting. Shareholders who wish to vote at the General Meeting must submit the Proxy Form by 10 a.m. on 15 January 2024. The Board of Directors of the Company and the independent non-executive directors recommend that shareholders approve the ordinary resolution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more